Finally, we identified a novel 13-irlncRNA signature and established a risk model to evaluate TNBC prognosis, as well as the correlation between clinicopathologic variables and the PD-L1 level or tumor mutational burden (TMB) score. Here, CD274 is linked to neoplasm.